James J. Dignam

Active 1993–2025

73
Papers
20,392
Citations
57
h-index
72
i10-index

Citations

Citations per year for James J. Dignam1974: 1 citations1994: 1 citations1995: 2 citations1996: 4 citations1997: 11 citations1998: 42 citations1999: 51 citations2000: 53 citations2001: 86 citations2002: 79 citations2003: 82 citations2004: 64 citations2005: 95 citations2006: 90 citations2007: 91 citations2008: 106 citations2009: 98 citations2010: 135 citations2011: 125 citations2012: 149 citations2013: 126 citations2014: 127 citations2015: 179 citations2016: 123 citations2017: 160 citations2018: 128 citations2019: 565 citations2020: 605 citations2021: 542 citations2022: 449 citations2023: 279 citations2024: 506 citations2025: 208 citations2026: 8 citations1975–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,734 citing papers, 32.7% of this breakdownUnited Kingdom: 555 citing papers, 6.6% of this breakdownCanada: 457 citing papers, 5.5% of this breakdownGermany: 436 citing papers, 5.2% of this breakdownChina: 406 citing papers, 4.9% of this breakdownItaly: 405 citing papers, 4.9% of this breakdownFrance: 338 citing papers, 4% of this breakdownNetherlands: 278 citing papers, 3.3% of this breakdownAustralia: 245 citing papers, 2.9% of this breakdownSwitzerland: 245 citing papers, 2.9% of this breakdownBelgium: 193 citing papers, 2.3% of this breakdownSpain: 178 citing papers, 2.1% of this breakdown
0%32.7%Other 22.7%

Fields

  • Medicine64%
  • Biochemistry, Genetics and Molecular Biology28.8%
  • Immunology and Microbiology1.7%
  • Neuroscience0.8%
  • Computer Science0.7%
  • Physics and Astronomy0.6%
  • Other3.4%

Topics

  • Breast Cancer Treatment Studies7.1%
  • Glioma Diagnosis and Treatment5.2%
  • Prostate Cancer Diagnosis and Treatment4.1%
  • Prostate Cancer Treatment and Research3.8%
  • Breast Lesions and Carcinomas3.3%
  • Head and Neck Cancer Studies2.9%
  • Other73.6%

Coauthors

All papers

Open in search
  1. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 2,793

  2. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2018 cited by 1,295

  3. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard and 1 more - The Lancet Oncology 2021 cited by 348

  4. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Godwin, Sam James, Amanda Kerr, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Mariko Nakahara, Simon Read, Hannah Taylor, John Ferguson, H Scheurlen, Stefano Zurrida, Viviana Galimberti, James N. Ingle, Pinuccia Valagussa, Umberto Veronesi, Stewart Anderson, Gong Tang, Bernard Fisher, Sophie D. Fosså, Kristin V. Reinertsen, Herman Høst, Hyman B. Muss, Kaija Holli, Kathy S. Albain, R. Arriagada, John M.S. Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa A. Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, José Á. García-Sáenz, Rich Gelber, Michael Gnant, Matthew P. Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Stuart McIntosh, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Martine Piccart, Lori J. Pierce, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Roberto Salgado, Dennis J. Slamon, Tanja Španić and 14 more - The Lancet 2023 cited by 151

  5. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 434

  6. Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2019 cited by 409

  7. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 662

  8. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 629

  9. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 123

  10. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 cited by 148

  11. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations

    Authors: , - JCO Precision Oncology 2019 cited by 105

  12. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel E. Spratt - JAMA Oncology 2020 cited by 102

  13. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

    Authors: , , , , , , , , - Journal of Clinical Oncology 2012 cited by 586

  14. Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 cited by 486

  15. The Use and Interpretation of Competing Risks Regression Models

    Authors: , , - Clinical Cancer Research 2012 cited by 363

  16. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses

    Authors: , , , , , , , , - JNCI Cancer Spectrum 2019 cited by 96

  17. Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2002 cited by 696

  18. Choice and Interpretation of Statistical Tests Used When Competing Risks Are Present

    Authors: , - Journal of Clinical Oncology 2008 cited by 269

  19. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

    Authors: , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2011 cited by 780

  20. Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 139

  21. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202

    Authors: , , , , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2017 cited by 138

  22. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 1998 cited by 896

  23. Statistical Considerations in the Evaluation of Continuous Biomarkers

    Authors: , - Journal of Nuclear Medicine 2021 cited by 42

  24. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 19